Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...
200.7 x 175.3 cm. (79 x 69 in.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback